BiotechTube
ARTHEx Biotech

ARTHEx Biotech

Valencia, Spain· Est.
arthexbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $62.5M

Overview

ARTHEx Biotech is a private, clinical-stage biotech developing first-in-class anti-microRNA (anti-miR) therapies. The company's core technology involves oligonucleotides conjugated to fatty acids for improved tissue delivery, initially targeting the root cause of myotonic dystrophy type 1 (DM1). With its lead candidate, ATX-01, now in clinical trials (the ArthemiR trial), ARTHEx is positioned in the competitive RNA therapeutics space with a differentiated mechanism aimed at a severe, orphan genetic disease. The company is backed by a syndicate of European and US venture capital firms.

Neuromuscular DiseasesGenetic Disorders

Technology Platform

Proprietary anti-microRNA (anti-miR) oligonucleotides conjugated to fatty acids for enhanced tissue delivery, particularly to muscle.

Funding History

3
Total raised:$62.5M
Venture$42M
Series A$15M
Seed$5.5M

Opportunities

The primary opportunity is addressing the high unmet need in myotonic dystrophy type 1 (DM1), a severe orphan disease with no disease-modifying therapies.
Success with ATX-01 would validate the anti-miR platform, enabling expansion into other microRNA-driven diseases in neurology, cardiology, and oncology.
The growing RNA therapeutics market and orphan drug incentives provide a favorable commercial environment.

Risk Factors

Key risks include clinical trial failure of ATX-01, competition from other companies developing DM1 therapies, and the challenge of securing sufficient funding to advance through late-stage development.
The novel anti-miR mechanism also carries inherent biological and safety uncertainties that must be proven in humans.

Competitive Landscape

ARTHEx competes in the DM1 space with companies like Dyne Therapeutics (FORCE platform), PepGen (PPMO platform), and others developing antisense or gene therapy approaches. In the broader anti-miR field, it faces competition from more established RNA therapeutics companies (e.g., Regulus Therapeutics, now dissolved, but with legacy programs) and large pharma exploring the modality. ARTHEx's differentiation lies in its specific microRNA target and its fatty acid conjugate delivery system.

More companies in RNA Therapeutics (non-mRNA) →More companies in Spain →